Outlook Therapeutics (NASDAQ: OTLK)
$7.58
(-1.9%)
-$0.15
Price as of May 10, 2024, 4:00 p.m. ET
Outlook Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Outlook Therapeutics Company Info
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.
News & Analysis
Featured Article
Why Shares of Outlook Therapeutics Rose Tuesday
The healthcare stock hit a 52-week high for the second consecutive day.
Jim Halley | Jun 6, 2023
Featured Article
Why Outlook Therapeutics Stock Surged Today
Investors are excited about the potential of the drugmaker's experimental wet AMD treatment.
Joe Tenebruso | Aug 3, 2021
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.